Einhorn L H, Bond W H, Hornback N, Joe B T
Semin Oncol. 1978 Sep;5(3):309-13.
Fifty eight patients with small cell carcinoma of the lung were treated with a combined-modality regimen: chemotherapy with adriamycin, cyclophosphamide, and vincristine; BCG immunotherapy; radiotherapy to the lung primary and prophylactic cranial irradiation. Ninteen patients had limited disease, and 39 had extensive disease. There were 27 (48%) partial remissions and 23 (41%) complete remissions, and median survival was 51 wk. Initial performance status and extent of disease had a definite effect on survival. Only 1 patient developed CNS metastases on prophylactic cranial irradiation. Five of 19 patients (26%) with limited disease remain alive and in complete remission at 26-45+ mo. It is becoming clear from this and other recent studies that we can significantly prolong median survival in small cell lung cancer. However, even more important is the fact that limited-extent small cell lung cancer may be a potentially curable disease.
58例小细胞肺癌患者接受了综合治疗方案：采用阿霉素、环磷酰胺和长春新碱进行化疗；卡介苗免疫治疗；对肺部原发灶进行放疗以及预防性颅脑照射。19例患者为局限性疾病，39例为广泛性疾病。有27例（48%）部分缓解，23例（41%）完全缓解，中位生存期为51周。初始身体状况和疾病范围对生存期有明确影响。仅1例患者在预防性颅脑照射时发生中枢神经系统转移。19例局限性疾病患者中有5例（26%）在26至45多个月时仍存活且处于完全缓解状态。从这项研究和其他近期研究中越来越清楚的是，我们可以显著延长小细胞肺癌的中位生存期。然而，更重要的是，局限性小细胞肺癌可能是一种潜在可治愈的疾病。
